Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Cancer is one of the leading causes of mortality globally thereby to cope with the cancer it is necessary to develop anticancer drugs. Diarylheptanoids, a natural product, are attractive to researchers owing to their intriguing structures and potent biological activities. In this article, considering the development of anticancer drugs with enhanced selectivity towards cancerous cells, a series of Cyclic Diarylheptanoids (CDHs) were designed, synthesized and evaluated their biological activity. To establish an easy route for the synthesis of diarylheptanoids and searching for anticancer drugs among CDHs by evaluating antiproliferative, and topoisomerase-I & -IIα inhibitory activities. Diarylheptanoids were synthesized from reported linear diarylheptanoids using classical Ullmann reaction. Antibacterial activity was evaluated by filter paper disc diffusion method. Cell viability was assessed by measuring mitochondrial dehydrogenase activity with a Cell Counting Kit (CCK-8). Topoisomerases I and II (topo-I and -IIα) inhibitory activity was measured by the assessment of relaxation of supercoiled pBR322 plasmid DNA. IFD protocol of Schrodinger Maestro v11.1 was used to characterize the binding pattern of studied compounds with the ATPase domain of the human topo-IIα. The synthesized CDHs were evaluated for their biological activities (antibacterial, antiproliferative, and topoisomerase-I & -IIα inhibitory activities, respectively). A series of anticancer agents was obtained through the prevention of their inhibitory activities against different microbes, which improved their selectivity for cancer cells. In brief, most of the synthesized CDHs had excellent antiproliferative activity against T47D (human breast cancer cell line). Pterocarine possessed the strongest activity (2i; IC50 = 0.63μM) against T47D. The cyclic diarylheptanoid 2b induced 30% inhibition of topoisomerase-IIα activity at 100μM compared with the reference of etoposide, which induced 72% inhibition. Among the compounds tested, galeon (2h) displayed very low activity against four bacterial strains. Compounds 2b, 2h and 2i formed hydrogen bonds with Thr215, Asn91, Asn120, Ala167, Lys168 and Ile141 residues, which are important for binding of ligand compound to the ATPase binding site of topoisomerase IIα by acting as ATP competitive molecule validated by docking study. In silico Absorption, Distribution, Metabolism and Excretion (ADME) analysis revealed the predicted ADME parameters of the studied compounds which showed recommended values. A series of CDHs were synthesized, evaluated their antibacterial, antiproliferative, and topo-I & -IIα inhibitory activity. SARs study, molecular docking study and in silico ADME analysis were conducted. Five compounds showed excellent and selective antiproliferative activity against the human breast cancer cell line (T47D). A compound showed topo-IIα activity by 30% at 100μM, which represents a moderate intensity of inhibition compared with etoposide. Three compounds formed hydrogen bonds with Thr215, Asn91, Asn120 and Ala167 residues, which are considered as crucial residues for binding to the ATPase domain of topoisomerase IIα. According to in silico drug likeness property analysis, three compounds are expected to show superiority over etoposide in case of absorption, distribution, metabolism and excretion.